PRGO -

. Currency in USD
87.10
+0.06 (+0.07%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close87.04
Open87.04
BidN/A x N/A
AskN/A x N/A
Day's Range86.85 - 88.80
52 Week Range63.68 - 95.93
Volume626,325
Avg. VolumeN/A
Market Cap12.267B
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-9.21
Earnings DateFeb 27, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est90.33
Trade prices are not sourced from all markets
  • NYSE trader: UnitedHealth and other oligopolies just got Amazon'd
    Yahoo Finance Video22 days ago

    NYSE trader: UnitedHealth and other oligopolies just got Amazon'd

    Keith Bliss of Cuttone and Company joins Yahoo Finance's Melody Hahm from the floor of the New York Stock Exchange to discuss the latest in the markets after Warren Buffett, Jeff Bezos and Jamie Dimon announced their taking their employees' health care into their own hands.

  • Is a Beat in the Cards for Perrigo (PRGO) in Q4 Earnings?
    Zacks8 hours ago

    Is a Beat in the Cards for Perrigo (PRGO) in Q4 Earnings?

    Perrigo's (PRGO) product purchases and launches in the Rx segment might boost sales in the coming quarters.

  • The Wall Street Journal19 hours ago

    Trial Tests FTC’s Power to Referee Drug Makers’ Fight Against Generics

    A trial under way in federal court in Philadelphia is testing the power of U.S. competition regulators to crack down on drug makers’ alleged moves to thwart the sale of low-cost generics.

  • CNBCyesterday

    Amazon has quietly launched an exclusive line of over-the-counter health products

    The products could spark a price war and put pressure on other store-brand profit margins.

  • MarketWatchyesterday

    Perrigo shares decline 1% on news of Bayer lawsuit over generic rosacea product

    Perrigo Co. PLC shares declined 1.2% in premarket trade Tuesday after the company said Bayer AG is suing it over a generic rosacea product after Perrigo filed for Food and Drug Administration approval ...

  • Perrigo Confirms Patent Challenge For Generic Version Of Finacea® Foam, 15%
    PR Newswireyesterday

    Perrigo Confirms Patent Challenge For Generic Version Of Finacea® Foam, 15%

    TASE: PRGO) today announced that it has filed a Paragraph IV Abbreviated New Drug Application with the U.S. Food and Drug Administration for a generic version of Finacea® Foam (azelaic acid foam, 15%). Following notification from Perrigo, Bayer AG filed a patent litigation suit asserting patents listed in the Orange Book for Finacea® Foam in the United States District Court for the District of Delaware on February 15, 2018. Finacea® Foam, 15% is a topical prescription medicine used to treat the inflammatory papules (raised spots) and pustules (pimple-like bumps) of mild to moderate rosacea.

  • See what the IHS Markit Score report has to say about Perrigo Company PLC.
    Markityesterday

    See what the IHS Markit Score report has to say about Perrigo Company PLC.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Perrigo Appoints Ronald L. Winowiecki as Chief Financial Officer
    PR Newswireyesterday

    Perrigo Appoints Ronald L. Winowiecki as Chief Financial Officer

    TASE: PRGO), a leading global provider of Quality Affordable Healthcare Products®, today announced that Ronald L. Winowiecki has been appointed Chief Financial Officer. Winowiecki has served as Acting CFO since February 2017. Perrigo President and CEO Uwe Roehrhoff commented, "I am pleased to announce the appointment of Ron as CFO of Perrigo.

  • Does Perrigo Company plc’s (NYSE:PRGO) Past Performance Indicate A Stronger Future?
    Simply Wall St.2 days ago

    Does Perrigo Company plc’s (NYSE:PRGO) Past Performance Indicate A Stronger Future?

    Measuring Perrigo Company plc’s (NYSE:PRGO) track record of past performance is a useful exercise for investors. It enables us to understand whether or not the company has met or exceedRead More...

  • See what the IHS Markit Score report has to say about Perrigo Company PLC.
    Markit5 days ago

    See what the IHS Markit Score report has to say about Perrigo Company PLC.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Perrigo Announces Quarterly Dividend
    PR Newswire6 days ago

    Perrigo Announces Quarterly Dividend

    Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products®. Founded in 1887 as a packager of home remedies, Perrigo has built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network. Perrigo is one of the world's largest manufacturers of over-the-counter ("OTC") healthcare products and suppliers of infant formulas for the store brand market.

  • See what the IHS Markit Score report has to say about Perrigo Company PLC.
    Markit12 days ago

    See what the IHS Markit Score report has to say about Perrigo Company PLC.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Perrigo To Release Fourth Quarter And Calendar Year 2017 Financial Results On February 27, 2018
    PR Newswire13 days ago

    Perrigo To Release Fourth Quarter And Calendar Year 2017 Financial Results On February 27, 2018

    TASE: PRGO) today announced that it will release its fourth quarter and calendar year 2017 financial results on Tuesday, February 27, 2018. The Company will also host a conference call beginning at 9:30 a.m. (EST). Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products®.

  • Perrigo Announces Tentative FDA Approval For The Generic Version Of Soolantra® Cream, 1%
    PR Newswire22 days ago

    Perrigo Announces Tentative FDA Approval For The Generic Version Of Soolantra® Cream, 1%

    TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Soolantra® (ivermectin) cream, 1%. Perrigo Executive Vice President and President Rx Pharmaceuticals John Wesolowski stated, "This is the Rx team's fifth generic product approval this month. Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products®.

  • Perrigo Announces Tentative FDA Approval For The Generic Version Of Onexton® Gel
    PR Newswire26 days ago

    Perrigo Announces Tentative FDA Approval For The Generic Version Of Onexton® Gel

    TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Onexton® Gel (clindamycin phosphate 1.2% and benzoyl peroxide 3.75%). Onexton® Gel (clindamycin phosphate 1.2% and benzoyl peroxide 3.75%) is a prescription medicine indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. Perrigo Executive Vice President and President Rx Pharmaceuticals John Wesolowski stated, "This tentative approval is another example of making long-term investments in our extended topicals strategy.

  • ACCESSWIRE26 days ago

    Blog Exposure - FDA Granted Final Approval to a Generic Version of Perrigo’s Estrace Cream

    LONDON, UK / ACCESSWIRE / January 26, 2018 / Active-Investors.com has just released a free research report on Perrigo Co. PLC (NYSE: PRGO ). If you want access to this report all you need to do is sign ...

  • GlaxoSmithKline Could Witness Modest Rise in Revenues in 2017
    Market Realist27 days ago

    GlaxoSmithKline Could Witness Modest Rise in Revenues in 2017

    GlaxoSmithKline (GSK) is a leading player in the global respiratory market with a major focus on the asthma and chronic obstructive pulmonary disease (or COPD) segments. The company has estimated global asthma prevalence to be around 250 million with 40% of the treated patients continuing to witness symptoms that affect the quality of their lives. To capitalize on this unmet demand, GlaxoSmithKline aims to deliver the right inhaled corticosteroid (or ICS) or combination regimen to the right patients and to ensure proper drug adherence.

  • What Analysts Recommend for GlaxoSmithKline in January 2018
    Market Realist27 days ago

    What Analysts Recommend for GlaxoSmithKline in January 2018

    In 3Q17, GlaxoSmithKline (GSK) reported global sales close to 7.8 billion pounds, which is a year-over-year (or YoY) rise of 2% on a constant exchange rate (or CER) basis and 4% YoY growth on an actual exchange rate (or AER) basis. The company reported earnings per share (or EPS) close to 24.8 pounds in 3Q17, which is a YoY rise of 46% on a CER basis and 49% on an AER basis. GlaxoSmithKline also reported adjusted EPS close to 32.5 pounds in 3Q17 and expects to witness a 3% to 5% YoY rise in adjusted EPS for 2017.

  • Pfizer: Revenue Growth Is Expected in 4Q17
    Market Realist27 days ago

    Pfizer: Revenue Growth Is Expected in 4Q17

    What to Expect from Pfizer’s 4Q17 Earnings on January 30

  • Perrigo Announces Final FDA Approval Of A Generic Version Of Estrace® Cream
    PR Newswire28 days ago

    Perrigo Announces Final FDA Approval Of A Generic Version Of Estrace® Cream

    Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products®. Founded in 1887 as a packager of home remedies, Perrigo has built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network. Perrigo is one of the world's largest manufacturers of over-the-counter ("OTC") healthcare products and suppliers of infant formulas for the store brand market.

  • Perrigo Announces Final FDA Approval And Launch Of An AB Rated Generic Version Of Epiduo® Gel
    PR Newswire28 days ago

    Perrigo Announces Final FDA Approval And Launch Of An AB Rated Generic Version Of Epiduo® Gel

    Perrigo Executive Vice President and President Rx Pharmaceuticals John Wesolowski stated, "This launch exemplifies Perrigo's commitment to developing and launching products within the extended topicals category. Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products®. Founded in 1887 as a packager of home remedies, Perrigo has built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network.

  • Perrigo (PRGO) Hits 52-Week High: What's Driving the Stock?
    Zackslast month

    Perrigo (PRGO) Hits 52-Week High: What's Driving the Stock?

    We look at the factors that drive the share price of Perrigo to a 52-week high.

  • Is Valeant Pharmaceuticals Intl Inc a Buy? 3 Pros, 3 Cons
    InvestorPlacelast month

    Is Valeant Pharmaceuticals Intl Inc a Buy? 3 Pros, 3 Cons

    Valeant Pharmaceuticals Intl Inc (NYSE: VRX) has been on a tear in recent months, nearly doubling since November 1, when it closed at $11.93 a share. Valeant announced its results on November 7, with the news it beat analyst estimates for both revenue and net income. The company has also made progress in reducing its substantial debt burden.

  • Recent Developments for Mylan
    Market Realistlast month

    Recent Developments for Mylan

    Who’s Watching Mylan in January 2018?

  • Elagolix May Advance the Treatment Paradigm in Women’s Health
    Market Realistlast month

    Elagolix May Advance the Treatment Paradigm in Women’s Health

    On October 27, 2017, AbbVie (ABBV) announced that the New Drug Application (or NDA) for its investigational drug Elagolix, which is used for managing endometriosis-related pain, had been granted priority review by the FDA. AbbVie has developed Elagolix in collaboration with Neurocrine Biosciences (NBIX). AbbVie expects this oral gonadotropin-releasing hormone (or GnRH) antagonist to be approved by its Prescription Drug User Fee Act (or PDUFA) date in 2Q18.